Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk

K Brennan; M Garcia-Closas; N Orr; O Fletcher; M Jones; A Ashworth; A Swerdlow; H Thorne; E Riboli; P Vineis; M Dorronsoro; F Clavel-Chapelon; S Panico; NC Onland-Moret; D Trichopoulos; R Kaaks; KT Khaw; R Brown; JM Flanagan

Journal article

Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk

K Brennan, M Garcia-Closas, N Orr, O Fletcher, M Jones, A Ashworth, A Swerdlow, H Thorne, E Riboli, P Vineis, M Dorronsoro, F Clavel-Chapelon, S Panico, NC Onland-Moret, D Trichopoulos, R Kaaks, KT Khaw, R Brown, JM Flanagan

Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2012

DOI: 10.1158/0008-5472.CAN-11-3157

Abstract

Few studies have evaluated the association between DNA methylation in white blood cells (WBC) and the risk of breast cancer. The evaluation of WBC DNA methylation as a biomarker of cancer risk is of particular importance as peripheral blood is often available in prospective cohorts and easier to obtain than tumor or normal tissues. Here, we used prediagnostic blood samples from three studies to analyze WBC DNA methylation of two ATM intragenic loci (ATMmvp2a and ATMmvp2b) and genome-wide DNA methylation in long interspersed nuclear element-1 (LINE1) repetitive elements. Samples were from a case-control study derived from a cohort of high-risk breast cancer families (KConFab) and nested case-..

View full abstract

University of Melbourne Researchers

Heather Thorne Author

Related Projects (2)

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

Grants

Awarded by Seventh Framework Programme

Funding Acknowledgements

This work was funded by Breast Cancer Campaign fellowship to J.M. Flanagan and Cancer Research UK program C536/A6689 to R. Brown. J.M. Flanagan and K. Brennan are funded by Breast Cancer Campaign. The Clinical Follow Up Study was funded by NHMRC grants 145684, 288704, and 454508. KConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The authors thank Breakthrough Breast Cancer and the Institute of Cancer Research for support and funding of the Breakthrough Generations Study. The ICR also acknowledges NHS funding to the NIHR Biomedical Research Centre. The EPIC cohort is supported by the Europe Against Cancer Program of the European Commission (SANCO).